HLN.L

Haleon plc
Haleon PLC - Directorate Change
1st May 2024, 10:10
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8322M
Haleon PLC
01 May 2024
 

 

 

 


Haleon plc announces changes to the Board

 

 

1 May 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that following Deirdre Mahlan's appointment as President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc. (NYSE: NAPA), Deirdre will be stepping down from her role as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon. Deirdre has agreed to continue as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon until a successor has been identified.

 

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Deirdre for her considerable contributions to the Board and for chairing the Audit & Risk Committee. I wish her all the best for the future. A search for her successor is now underway."

 

 

 

 

Contacts

Zoë Bird                +44 7736 746167

Sonya Ghobrial      +44 7392 784784

Email: corporate.media@haleon.com

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUPUMUAUPCGUG]]>
TwitterFacebookLinkedIn